Zacks15d agoneutral
STERIS' Q1 Earnings on Deck: What's in Store for the Stock?STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
314last 24h
2130last 7d
379● bullish (7d)
183● bearish (7d)
204publishers
MarketBeat20d agoneutral
West Pharmaceutical Services Q2 Earnings Call HighlightsWest Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C
Moby20d agoneutral
West Pharmaceutical Services, Inc. Q2 2026 Earnings Call SummaryMoby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call
GuruFocus.com20d agoneutral
West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highlights: Strong Organic Growth ...West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.
MT Newswires21d agoneutral
West Pharmaceutical Services Q2 Adjusted Earnings, Net Sales Rise; 2026 Outlook BoostedWest Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share
Zacks22d agoneutral
Omnicell to Report Q2 Earnings: OmniSphere in FocusOMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.
Barchart41d agoneutral
What to Expect From West Pharmaceutical Services' Q2 2026 Earnings ReportWest Pharmaceutical Services will release its second-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.